Clinical Trial Update: Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Tanespimycin in combination with Cytarabine in adults with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia | Phase 1 | Status: COMPLETED